Marcus Chen
Senior Market Analyst
Senior Market Analyst at 13F Insight. Covers institutional portfolio strategy, 13F filings, and smart money trends.
A note from Marcus
Hi, I'm Marcus. I spent six years on the buy side staring at 13F filings for a hedge fund, and the thing that bothered me most wasn't the work — it was knowing that the average investor never gets to see what I was looking at, even though it's all public.
That's why I'm here. Every research piece you'll see under my name comes from real SEC data, run through real institutional logic, and translated into something you can actually act on. I write long when the data deserves it and short when it doesn't.
If you ever spot a number that looks off, email me. I'd rather be corrected than wrong.
Articles by Marcus Chen (524)
- Research
Mawer 13F (2026 Q1): A Global-Quality Book in Broad Retreat
Mawer, the Calgary firm whose motto is be boring, make money, runs a patient global-quality book. Its 2026 Q1 US filing shows broad retreat, nearly every major position trimmed and reported value down from $22B to $15B, the fingerprint of outflows rather than lost conviction.
- Research
Mairs & Power 13F (2026 Q1): Megacaps and a Minnesota Tilt
Mairs & Power has managed money from St. Paul since 1931, and its book carries a hometown accent. Its 2026 Q1 13F pairs a megacap-tech core, Nvidia, Microsoft, Amazon, with prominent Minnesota industrials like Graco and Toro, a quality-growth discipline rooted in local knowledge.
- Research
Westwood Global 13F (2026 Q1): 12 Stocks, Mostly Latin America
Westwood Global runs emerging-markets investing the rare way: just 12 high-conviction positions, mostly Latin American. Its 2026 Q1 book is anchored by Credicorp and Itaú, with a 78% add to Argentina's Grupo Galicia and a new Yum China stake, a focused regional wager, not diversified EM.
- Research
First Pacific Advisors 13F (2026 Q1): Value With a Quality Streak
First Pacific Advisors occupies the middle ground of value investing, owning unloved value names and high-quality compounders side by side when the price is right. Its 2026 Q1 book pairs Analog Devices and Alphabet with Citigroup and Comcast, while trimming several winners.
- Research
Pinnacle Associates 13F (2026 Q1): Stocks and ETFs Side by Side
Pinnacle Associates' 2026 Q1 13F blends hand-picked megacaps, Johnson & Johnson, Apple, Nvidia, with broad-market index ETFs like SPY, VTI and a new Nasdaq-100 sleeve. A core-satellite book that shows where the firm bets actively and where it is content to own the market.
- Research
Crawford Investment 13F (2026 Q1): An Income-and-Quality Book
Crawford Investment Counsel builds around high-quality companies that pay and grow reliable dividends. Its 2026 Q1 book spreads $5.85B across 300 income payers, with a utility-and-staples backbone, AbbVie, AstraZeneca, AEP, Philip Morris, and a new AstraZeneca stake.
- Research
Cardinal Capital 13F (2026 Q1): A Canadian Blue-Chip Book
Cardinal Capital's 2026 Q1 13F reads like the Toronto exchange: a concentrated 66-stock book anchored by Suncor, the big Canadian banks, pipelines and life insurers. A dividend-rich bet on Canada's resource and financial economy, headlined by a doubling of its Sun Life position.
- Research
Auxier 13F (2026 Q1): A Capital-Preservation Value Book
Jeff Auxier runs money to protect capital first and let returns follow. His 2026 Q1 book spreads $696M across 176 mostly defensive names, Philip Morris, Kroger, Walmart, Microsoft, J&J, with only light trims, the texture of a downside-aware, capital-preservation strategy.
- Research
Beck Mack & Oliver 13F (2026 Q1): A Bet on Private Capital
Beck Mack & Oliver, a New York firm dating to the 1930s, leans into a modern theme in 2026 Q1: the rise of the alternative-asset managers. Its book is led by Apollo and Blackstone, with Schwab and Gallagher alongside, a quality-financials tilt toward private-market finance.
- Research
Broad Run 13F (2026 Q1): A 24-Stock Book, One 21% Bet
Broad Run takes concentration literally: 24 positions, with AST SpaceMobile alone at 21% of the book. Its 2026 Q1 filing pairs that outsized, speculative bet with a core of quality compounders, Applied Materials, Brookfield, Markel, O'Reilly, conviction expressed without a safety net.
- Research
Cullen Capital 13F (2026 Q1): A High-Dividend Value Book
Cullen invests in value through the dividend lens, favoring large, cash-returning businesses that pay above-market yields at modest valuations. Its 2026 Q1 book spreads $9.75B across 213 dividend payers, pharma, banks, utilities and energy, with nothing above 3.2%.
- Research
Fenimore (FAM) 13F (2026 Q1): A Quality-Compounder Book
Fenimore's FAM Funds buy well-run, durable businesses and hold them for years. Its 2026 Q1 book spreads $4.48B across 92 quality compounders, Ross Stores, Amphenol, Stryker, Fastenal, Markel, with only light trims, the texture of a patient, low-turnover strategy.
- Research
Weitz 13F (2026 Q1): Omaha Quality-Value, Anchored by Berkshire
Wally Weitz built one of Omaha's most respected value shops, and his 2026 Q1 book is fittingly anchored by Berkshire Hathaway. A focused, quality-tilted portfolio held steady this quarter, with one clear move: a 16% add to Microsoft.
- Research
Jensen 13F (2026 Q1): A Strict-Quality Fund Trims Megacap Tech
Jensen only owns businesses that have earned 15%-plus return on equity for ten straight years. Its 2026 Q1 book of proven compounders shows the firm de-risking megacap tech, trimming Apple and Nvidia, even as sustained outflows have halved its reported assets.
- Research
Cooke & Bieler 13F (2026 Q1): A Diffuse Value Book
Cooke & Bieler, a long-established Philadelphia value boutique, runs a diffuse 100-name book where no stock tops 4%. Its 2026 Q1 filing leans heavily on specialty insurers, RenaissanceRe, White Mountains, Arch, which it trimmed, alongside a new Sunbelt Rentals stake.
- Research
Kahn Brothers 13F (2026 Q1): Deep Value in the Graham Tradition
Kahn Brothers, founded by Benjamin Graham's own teaching assistant Irving Kahn, practices deep value in its purest, most contrarian form. Its concentrated 2026 Q1 book is led by Citigroup and Bayer, with hard trims in Merck and BP and a new Zillow stake.
- Research
Davenport 13F (2026 Q1): How to Read an Advisor's Whole Book
Davenport's 13F is not a hedge fund's conviction book but a Virginia wealth advisor's aggregated holdings, about 500 names where nothing tops 2.4%. Read as a barometer of broad allocation, its 2026 Q1 drift tilted toward megacap tech, Berkshire and managed care.
- Research
Chilton Investment 13F (2026 Q1): A Quality Core, Retail Trimmed
Chilton's 2026 Q1 filing lists about 280 names, but a concentrated quality core does the work, with the top ten above half of value. The quarter's moves show a measured rotation: trimming Costco and Home Depot while adding 57% more Amazon.
- Research
Mar Vista 13F (2026 Q1): A Wide-Moat Book Leaning Into AI
Mar Vista's quality-growth book is built on wide-moat businesses with the free cash flow to compound. In 2026 Q1 it held its megacap core flat while leaning hard into AI hardware, adding 68% more Broadcom and 14% more Nvidia, even as assets dipped below $1B.
- Research
Lindsell Train 13F (2026 Q1): A Broad Trim, Two Conviction Adds
Nick Train's Lindsell Train holds a tiny set of durable, brand-rich businesses and trades rarely. In 2026 Q1 it cut most of its 27-stock US book amid outflows, but leaned into two software-and-data franchises, Intuit and FICO, a telling conviction signal.